Following Cathie Wood: Aggressively buying chip dark horse CBRS for two consecutive days, taking profits at highs on Taiwan Semiconductor and AMD

Eastern Time on Friday (May 15th), after the AI boom drove US stocks to repeated new highs, the three major US indices pulled back significantly amid rising international oil prices, fueling market concerns about global inflation.

In these market conditions, ARK Invest’s portfolio adjustments on May 15th continued the previous day’s strategy of 'hardware rotation' and 'biotech cleansing': on the buying side, it heavily added positions for two consecutive days in Cerebras Systems (CBRS), an AI chip disruptor; $Cerebras Systems (CBRS.US)$ on the selling side, it expanded profit-taking at higher levels in $Taiwan Semiconductor (TSM.US)$ 、 $Teradyne (TER.US)$and$Advanced Micro Devices (AMD.US)$ , while continuing to remove traditional medical diagnostic stocks CDNA and TWST from its core portfolio.

Buying direction: Aggressively purchased CBRS for two consecutive days, adding another 149,200 shares today.

Following the substantial initial position of 105,600 shares on May 14th, ARK further aggressively bought $Cerebras Systems (CBRS.US)$ 149,200 shares.Cerebras, a recent standout AI chip unicorn, is leveraging its breakthrough 'Wafer-Scale Engine (WSE)' technology to address data transmission bottlenecks in large AI model training on a single oversized chip. ARK's significant purchases over two consecutive days indicate that as the market expectations around traditional GPU architectures and foundry models become increasingly crowded, capital is now being precisely allocated towards emerging computing infrastructures with explosive monetization potential, capable of disrupting the current landscape in specific AI training scenarios.

Sell-side direction: Semiconductor giants accelerate profit-taking at highs, fully divesting from traditional healthcare.

Selling the global chip foundry leader $Taiwan Semiconductor (TSM.US)$Up to 59,000 shares, reducing stake in semiconductor testing equipment provider $Teradyne (TER.US)$35,000 shares, and AI chip giant $Advanced Micro Devices (AMD.US)$13,100 shares.Recently, driven by expectations of undersupply in AI production capacity, valuations in the semiconductor sector have repeatedly hit new highs. From the perspective of institutional investors, the positive outlook has already been largely priced into the stock prices. ARK’s decision to sell these three core companies in the semiconductor supply chain for two consecutive days reflects a classic 'profit-taking at highs' strategy, aimed at securing the substantial profits gained during the AI hardware boom and freeing up liquidity to build positions in emerging stars like Cerebras.

Continued selling $Twist Bioscience (TWST.US)$Total of 11,600 shares.This marks ARK's continued selling of this synthetic biology company over multiple days. In the current macro environment characterized by high capital costs, the market has little tolerance for loss-making enterprises. Withdrawing funds from TWST, whose commercialization process has been slow, represents a routine portfolio optimization move to improve capital efficiency.

Reduced holdings in Organ Transplant Diagnostics Company $CareDx (CDNA.US)$A total of 6,356 shares.This continues ARK Invest’s biotech portfolio adjustment logic since May. In the context of the strong rise of leading precision medicine companies, CDNA is facing challenges such as market share erosion and weak growth.

Futubull [Opportunities page] Now featuring the ability to track portfolios of renowned investors! Choose from multiple celebrity holdings, follow the investment strategies of top players with one click, accurately target high-quality stocks, and invest with greater confidence!

269K Views